Nexus Pharmaceuticals Launches Cyclophosphamide Injection, 2.5 mL and 5 mL [Yahoo! Finance]
Dr. Reddy's Laboratories Ltd (RDY)
US:NYSE Investor Relations:
drreddys.com/investors
Company Research
Source: Yahoo! Finance
As the first AP Rated Generic to Dr. Reddy's, this product provides healthcare providers with a critical chemotherapy medication that slows the growth of cancer cells. "Transforming difficult-to-formulate molecules into the highest-quality medicines is what we do best," says Stephen Kim, Chief Executive Officer at Nexus. "Bringing Cyclophosphamide to market is another example of our commitment to expand access to the critical treatments patients and providers rely on every day." Cyclophosphamide Injection is now available. Order through your Wholesaler or call (888) 806-4606. Cyclophosphamide Injection 500 mg/2.5 mL - Unit of Sale NDC 14789-0125-05 Cyclophosphamide Injection 1 gram/5 mL - Unit of Sale NDC 14789-0126-05 About Nexus Pharmaceuticals, LLC: Nexus Pharmaceuticals, LLC, a US-based healthcare company, specializes in innovative processes to make difficult-to-manufacture specialty and generic drugs that are easier to use, less labor intensive, and more streamlined i
Show less
Read more
Impact Snapshot
Event Time:
RDY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RDY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RDY alerts
High impacting Dr. Reddy's Laboratories Ltd news events
Weekly update
A roundup of the hottest topics
RDY
News
- Head and Neck Cancer Market to Expand at 7.8% CAGR During 2026-2030 as Immuno-Oncology Therapies Offer Promising Advances in HNC Treatments [Yahoo! Finance]Yahoo! Finance
- Ozempic copies for $14 as the generic GLP-1 era starts in India [Los Angeles Times (CA)]Los Angeles Times
- India's Zydus, Lupin sign deal to co-market Semaglutide injections [Yahoo! Finance]Yahoo! Finance
- Strait of Hormuz standoff puts supply of America's generic drug prescriptions at risk [MSNBC.com]MSNBC.com
- India Semaglutide Patent Expiry Could Drive 50% Price Drop in Weight-Loss Drugs [Yahoo! Finance]Yahoo! Finance
RDY
Earnings
- 1/22/26 - Beat
RDY
Sec Filings
- 4/1/26 - Form 3
- 4/1/26 - Form 3
- 4/1/26 - Form 3
- RDY's page on the SEC website